Home News Insights Trading halts Paper trading Guide Community My account

Market calendarChecking market schedule

Display in USD

Loading news article.

About WAPE
U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Copyright © WAPE. All rights reserved.

Loading news article.

HC Wainwright Maintains Buy Rating and Lowers Price Target for Akebia Therapeutics | WAPE

Newsfiscal.ai

HC Wainwright Maintains Buy Rating and Lowers Price Target for Akebia Therapeutics

Nov 7, 2026, 09:03 ET · Published

Article summary

HC Wainwright & Co. has reaffirmed its 'Buy' rating on Akebia Therapeutics while reducing its price target from $6 to $4.

An excerpt from the original article.

Related companies

Akebia Therapeutics, Inc. Common StockAKBAView stock

Analyzed by WAPE AI.

Preparing English content…

Comments —

Comment

Loading comments…